Cue Biopharma Completes Patient Enrollment in Ph1b Head & Neck Cancer Trial

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, today announced that it has completed patient enrollment in its Phase 1 clinical trial (NCT03978689) evaluating CUE-101, the company’s lead interleukin 2 (IL-2)-based biologic from the CUE-100 series, in combination with KEYTRUDA® (pembrolizumab) as first-line treatment for patients with human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC).

“Completing the enrollment of the recommended phase 2 dose patient expansion cohort is an important milestone as the data from this trial guides further development plans and associated discussions with the Food and Drug Administration (FDA),” said Daniel Passeri, chief executive officer of Cue Biopharma. “We believe the updated data will build upon the already promising clinical profile established to date, which has shown an enhancement of clinical efficacy with the CUE-101-pembrolizumab combination compared to pembrolizumab alone. With the strength of the data already observed with monotherapy in second line patients and beyond, combined with the promising combination data emerging in 1L with pembrolizumab, we plan to discuss potential registrational paths with the Food and Drug Administration (FDA) for CUE-101 both as a monotherapy and in combination with pembrolizumab, leveraging the Fast Track Designation previously granted to these programs.”

Matteo Levisetti, M.D., chief medical officer of Cue Biopharma added, “We believe the data from our CUE-101 trial represents a potential therapeutic breakthrough for HPV+ R/M HNSCC patients, bolstering our confidence in the platform to address unmet needs of patients suffering from a myriad of cancers. The maturing clinical data for CUE-101 further supports the mechanism of action which enables selective expansion of targeted tumor-specific T cells and also provides clinical validation and de-risking of our Immuno-STAT™ platform. This clinical validation is also being supported by a Phase 1 trial with our second CUE-100 series biologic, CUE-102, for Wilms’ Tumor 1-expressing tumors. Data to date has demonstrated clinical evidence of anti-tumor activity across multiple indications in patients treated in the dose escalation portion of the study, and we look forward to presenting the data at SITC.”

About the CUE-100 Series
The CUE-100 series consists of Fc-fusion biologics that incorporate peptide-MHC (pMHC) molecules along with rationally engineered IL-2 molecules. This singular biologic is anticipated to selectively target, activate and expand a robust repertoire of tumor-specific T cells directly in the patient’s body. The binding affinity of IL-2 for its receptor has been deliberately attenuated to achieve preferential selective activation of tumor-specific effector T cells while reducing the potential for effects on regulatory T cells (Tregs) or broad systemic activation, potentially mitigating the dose-limiting toxicities associated with current IL-2-based therapies.

 

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

OCSiAl’s exceptional graphene nanotubes -based solution addresses these issues, ushering in a new era of silicone PSA technology. The user-friendly nanotube dispersion TUBALLTM MATRIX 617 results in excellent electrical conductivity combined with more than 90% transparency in a wide range of peeling-strength PSA films.
“Our latest study is the result of six years of focused research, delivering a practical model that allows users to predict metabolic pathways for a wide range of drug-like compounds. Thanks to our carefully curated datasets and our signature reactivity-accessibility approach, we have managed to build accurate isoform-specific regioselectivity models for the important Phase I and II enzyme families” Dr Mario Öeren, Principal Scientist, Optibrium said
The Nevisense System is a first-of-its-kind AI-driven technology that uniquely addresses the complexities of point-of-care detection of the deadliest form of skin cancer by providing clinicians with advanced analysis of irregular moles during routine skin checks.
"We are pleased to enter into this collaboration with Lycia Therapeutics, extending our service footprint to the area of extracellular protein degradation. We believe Lycia's leveraging of our antibody discovery capabilities will help accelerate its efforts to advance novel protein degrader therapeutics," said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences said.
Through this named patient program in the Netherlands ('Leveren op Artsenverklaring'), physicians may seek individual access to TLX250-CDx for use in PET characterisation of renal masses as ccRCC. The first patient was dosed at Radboud University Medical Centre in Nijmegen, Netherlands.

By using this website you agree to accept Medical Device News Magazine Privacy Policy